Abstract
A 2014 CEA from the Singapore healthcare system perspective was published, claiming that Metformin and Lifestyle modification treatments were cost-effective in Pre-Diabetes. The analysis used ICERs and made a classic error in calculating ICERs vs. a common (Placebo) alternative. Our objective was to show NMB advantages over ICERs.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
